Tuberculosis (TB) is one of the world’s leading causes of death from a single infectious pathogen.
According to the World Health Organization (WHO), 1.25 million people died from TB in 2023. This was almost twice as many deaths as from HIV/AIDS. An estimated 10.8 million people became ill with TB in 2023, continuing the uptick in global cases that began in 2020 following the COVID-19 pandemic.
However, TB is preventable and curable.
FHI 360 is a global leader in TB research and programming. We support countries with a high TB burden to end TB by addressing challenges at national, regional and community levels across public and private sectors.
To advance the WHO End TB Strategy, which envisions a world free of TB, we work with local partners to create and deliver innovative TB programs.
30+
Countries in which we have projects focused on TB and/or TB/HIV
19 out of 30
Countries on the WHO’s high-burden TB list in which we’ve led TB projects since 2019
120+
Staff members working on TB projects
Our TB expertise
The TB epidemic has threatened human health since early human history. To protect and save lives, FHI 360 delivers TB technical assistance designed to align national efforts with international best evidence.
Simultaneously, we introduce game-changing innovations and new tools to help reduce TB incidence and mortality. We also strengthen service delivery for TB and comorbidities such as HIV and diabetes.
Maximizing detection
Our programs maximize efforts to find people of all ages with all forms of TB. We conduct active case finding in communities, including among vulnerable populations and in group settings, and intensified case finding in facilities. We also support the introduction and scale-up of digital screening tools and the strengthening of laboratory networks.
Ensuring treatment adherence and cures
We help people diagnosed with TB successfully complete treatment and be cured. We conduct comprehensive drug-susceptible and drug-resistant TB treatment and care through person-centered approaches extending into community and primary health care levels. This includes active drug safety monitoring and management as well as treatment adherence and monitoring.
Preventing TB
Our programs work to stop the spread of new infections as well as progression to active TB disease. We oversee systematic contact investigation and management, TB preventive treatment, and infection prevention and control measures.
Developing new tools and approaches
We innovate and scale up new tools and approaches to diagnose, trace and treat TB. This includes new drugs and regimens, social and behavioral change methodologies, and guidelines, research and advocacy.
Building country-owned TB systems
We enhance and accelerate progress of country-owned TB systems in partnership with national governments and local partners. We organize private sector engagements, health systems strengthening and multisectoral collaborations to catalyze progress toward universal health care through TB services.
To end the tuberculosis epidemic, the private sector must expand drug-resistant TB treatment
Projects
Current projects
Our projects increase access to high-quality TB prevention, diagnostics, treatment and care services for all. We also strengthen service delivery for drug-resistant TB and for TB and comorbidities.
Featured legacy projects
Since 2004, we have worked on global and national technical assistance projects to prevent, diagnose and treat TB, including leading and supporting efforts to integrate TB interventions within the overall health system.
Our work in high-burden TB countries
FHI 360 currently or has recently worked in 19 of the WHO’s 30 high-burden TB countries. Learn more about what we're doing for TB and other challenges in these countries (Lesotho not included):
